eurofins | Discovery Services

# PRODUCT DATASHEET

## ChemiScreen™ $CRF_1$ Corticotropin Releasing Factor Receptor Stable Cell Line

## CATALOG NUMBER: HTS023C

**CONTENTS**: 2 vials of mycoplasma-free cells, 1 mL per vial.

**STORAGE**: Vials are to be stored in liquid $N_2$.

## BACKGROUND

ChemiScreen cell lines are constructed in the Chem-1 host, which supports high levels of functional receptor expression on the cell surface. Chem-1 cells contain high endogenous levels of Gα15, a promiscuous G protein, allowing most receptors to couple to the calcium signaling pathway.

The $CRF_1$ receptor is a $G_s$-coupled GPCR expressed in the brain and pituitary gland that binds to several neuropeptides, including corticotropin-releasing factor (CRF) and urocortin, and the amphibian peptide sauvagine (Chen et al., 1993; Dautzenberg and Hauger, 2002; Bale and Vale, 2004). CRF plays a predominant role in stress response mediated by the hypothalamic-pituitary-adrenal axis, and alterations in CRF and its receptors $CRF_1$ and $CRF_2$ appear to be linked to depression and anxiety (Holsboer, 1999; Bale and Vale, 2004). A number of small molecule antagonists of the $CRF_1$ receptor have been characterized, including R121919, SC241, NBI27914, antalarmin, DMP-696, and CP 154,526. When delivered in animal models of psychiatric disorders, these antagonists display effectiveness in reducing stress-related behaviors (Kehne and De Lombaert, 2002). The cloned human $CRF_1$-expressing cell line is made in the Chem-1 host, which supports high levels of recombinant $CRF_1$ expression on the cell surface and contains high levels of the promiscuous G protein Gα15 to couple the receptor to the calcium signaling pathway. Thus, the cell line is an ideal tool for screening for antagonists of interactions between $CRF_1$ and its ligands.

## USE RESTRICTIONS

Please see **Limited Use Label License Agreement** (Label License Agreement) for further details.

## WARNINGS

For Research Use Only; Not for Use in Diagnostic Procedures
Not for Animal or Human Consumption

### GMO

This product contains genetically modified organisms.
Este producto contiene organismos genéticamente modificados.
Questo prodotto contiene degli organismi geneticamente modificati.
Dieses Produkt enthält genetisch modifizierte Organismen.
Ce produit contient organismes génétiquement des modifiés.
Dit product bevat genetisch gewijzigde organismen.
Tämä tuote sisältää geneettisesti muutettuja organismeja.
Denna produkt innehåller genetiskt ändrade organismer.

**Eurofins Pharma Bioanalytics Services US Inc.**
6 Research Park Drive
St Charles MO 63304
USA
T | +1 844 522 7787
F | +1 636 362 7131
www.eurofins.com

## APPLICATIONS

cAMP accumulation

## APPLICATION DATA




Figure 1. Representative data for activation of $CRF_1$ receptor stably expressed in Chem-1 cells induced by Urocortin using a cAMP accumulation assay. $CRF_1$–expressing Chem-1 cells were seeded at 50,000 cells per well into a 96-well plate, and the following day the cells were treated with Urocortin for 10 minutes in the presence of 100 µM IBMX and 0.5% DMSO to determine receptor-mediated cAMP generation or [with Urocortin for 10 minutes in the presence of 100 µM IBMX and 10 µM forskolin, to stimulate adenylate cyclase, and 0.5% DMSO to determine the receptor's ability to inhibit cAMP generation using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay measured on the BioTek Synergy. Maximal fluorescence signal obtained in this experiment was 7,000 RLU. Similarly parental cells (catalog #: HTSCHEM-1) were tested to determine the specificity of the resulting signal.

Table 1. $EC_{50}$ value of $CRF_1$-expressing Chem-1 cells.

| LIGAND | ASSAY | POTENCY $EC_{50}$ (nM) | REFERENCE |
|---|---|---|---|
| **Urocortin** | cAMP Accumulation | 106 | Eurofins Internal Data |

* The cell line was tested and found to have equivalent $EC_{50}$ and signal at 1, 3 and 6 weeks of continuous culture by calcium flux fluorescence.

## CELL CULTURE

Table 2. Recommended Cell Culture Reagents (not provided)

| Description | Component | Concentration | Supplier and Product Number |
|---|---|---|---|
| **Basal Medium** | DMEM high glucose Medium (4.5g/L) | - | Hyclone: SH30022 |
| | Fetal Bovine Serum (FBS) | 10% | Hyclone: SH30070.03 |
| | Non-Essential Amino Acids (NEAA) | 1X | Hyclone: SH30238.01 |
| | HEPES | 1X | EMD Millipore: TMS-003-C |
| **Selection Medium** | Basal Medium (see above) | - | |
| | Geneticin (G418) | 250 µg/ml | Invivogen: ant-gn-5 |
| **Dissociation** | Sterile PBS | - | Hyclone: SH30028.03 |
| | 0.25% Trypsin-EDTA | - | Hyclone: SH30042.01 |
| **CryoMedium** | Basal Medium (see above) | 40% | |
| | Fetal Bovine Serum (FBS) | 50% | Hyclone: SH30070.03 |
| | Dimethyl Sulfoxide (DMSO) | 10% | Sigma: D2650 |

## Cell Handling

1. Upon receipt, directly place cells in liquid nitrogen storage. Consistent cryopreservation is essential for culture integrity.
2. Prepare Basal Medium. Prepare 37ºC Water Bath. Thaw cells rapidly by removing from liquid nitrogen, and immediately immersing in a 37ºC water bath, until 90% thawed. Immediately sterilize the exterior of the vial with 70% ethanol.
3. Add vial contents to 15 mL Basal Medium in T75 Tissue Culture Treated Flask. Gently swirl flask and place in a humidified, tissue culture incubator, 37ºC, 5% $CO_2$.
4. 18-24 Hours Post–Thaw, all live cells should be attached. Viability of the cells is expected to be 60-90%, At this time, exchange Basal Medium with Selection Medium.
5. When cells are approximately 80% confluent, passage the cells. It is suggested that user expand culture to create >20 vial Master Cell Bank at low passage number. *Cells should be maintained at less than 80% confluency for optimal assay results.*
6. Cell Dissociation: Aspirate Culture Medium. Gently wash with 1x Volume PBS. Add 0.1x Volume Warm Trypsin-EDTA. Incubate 4 min, 37°C, until cells dislodge. *If cells do not round up, place in 37º C incubator for additional 2 min*. Neutralize Trypsin and collect cells in 1x Volume Basal Medium.
7. Seed Cells for expansion of culture. It is recommended that cell lines are passaged at least once before use in assays.

Table 3. Cell Culture Seeding Suggestions: *User should define based on research needs.*

| Flask Size ($cm^2$) | Volume (mL) | Total Cell Number ($x10^6$) | Growth Period (hrs) |
|---|---|---|---|
| **T75** | 15 | 5.0 | 24 |
| **T75** | 15 | 2.0 | 48 |
| **T75** | 15 | 0.45 | 72 |

# ASSAY SETUP

## Fluorescence

Table 4. Settings for FLIPR$^{TETRA}$® with ICCD camera option

| Option | Setting |
|---|---|
| Read Mode | Fluorescence |
| Ex/Em | Ex470_495 / Em515_575 |
| Camera Gain | 2000 |
| Gate Open | 6 % |
| Exposure Time | 0.53 |
| Read Interval | 1s |
| Dispense Volume | 50 µl (25 µl for 384-well) |
| Dispense Height | 95 µl (50 µl for 384-well) |
| Dispense Speed | 50 µl/sec |
| Expel Volume | 0 µl |
| Analysis | Subtract Bias Sample 1 |

Table 5. Assay Materials (Not provided)

| Description | Supplier and Product Number |
|---|---|
| HBSS | Invitrogen: 14025 |
| HEPES 1M Stock | EMD Millipore: TMS-003-C |
| Probenicid | Sigma: P8761 |
| Quest Fluo-8™, AM | AAT Bioquest: 21080 |
| Urocortin ligand | Tocris: 1604 |
| Non-Binding 96/384 well Plates (for ligand prep) | Corning: 3605/ 3574 |
| Black (clear Bottom) cell assay plates | Corning: 3904/ 3712 |
| Coelenterazine-h (250µg). Prepare to 10mM | Promega: S2011 |

## Assay Protocol – Fluorescence

1. Dissociate Culture as Recommended. Collect in Basal Medium. Document Cell Count and Viability
2. Centrifuge the cell suspension at 190 x g for six min
3. Remove supernatant. Gently resuspend the cell pellet in Basal Medium. *It is suggested that end user optimize cell plating based on individual formats.* (Default: Resuspend in volume to achieve $5x10^5$cells/ml *(i.e, if collected 5e6 TC,* $^{5e6/}_{5e5/ml}$ *=10 mL volume)*
4. Seed cell suspension into black, clear bottom plate (100 µL/well for 96-well plate). *When seeding is complete, place the assay plate at room temperature for 30 min.*
5. Move assay plate to a humidified 37ºC 5% $CO_2$ incubator for 18-24 h.
6. Next day, prepare Assay buffer (HBSS, 20mM HEPES, 2.5 mM Probenicid, pH 7.4) and Loading buffer (Assay buffer with 5 mM Fluo8 Dye). *Note: Please prepare Fluo8 stock according to Manufacturer's Recommendations*
7. Remove medium from assay plate and wash 1X with Assay Buffer.
8. Add Loading buffer to assay plate (100 µL/well for 96-well plate). Incubate plate for 1.5 h at room temperature, protected from light.
9. Prepare ligands in assay buffer at 3x final concentration in non-binding plates. Use Buffer Only Control Wells for Background Subtraction.
10. Create protocol for ligand addition. Please refer to FLIPR$^{TETRA}$® settings provided in Table 2. Set time course for 180 s, with ligand addition at 10 s.
11. After the run is complete, apply subtract bias on sample 1. We recommend using Negative Control Correction with Buffer Only Wells. Export data to according to research needs. For most Calcium Flux analysis using Export of Max Signal to end of run is sufficient.

## HOST CELL

Chem-1, an adherent cell line expressing the promiscuous G-protein, Gα15.

## EXOGENOUS GENE EXPRESSION

Human $CRF_1$ cDNA (Accession Number: X72304) and promiscuous G protein are expressed in a bicistronic vector

## RELATED PRODUCTS

| Product Number | Description |
|---|---|
| **HTSCHEM-1** | ChemiScreen™ Chem-1 Parental Cell Line (control cells) |
| **HTS023M** | ChemiScreen™ $CRF_1$ Corticotropin Releasing Factor Receptor Membrane Prep |

## REFERENCES


1. Bale TL and Vale WW (2004) CRF and CRF receptors: role in stress responsivity and other behaviors. *Annu. Rev. Pharmacol. Toxicol.* 44: 525-557.
2. Chen R., et al. (1993) Expression cloning of a human corticotropin-releasing factor receptor. *Proc. Natl. Acad. Sci. USA* 90: 8967-8971.
3. Dautzenberg FM and Hauger RL (2002) The CRF peptide family and their receptors: yet more partners discovered. *Trends Pharmacol. Sci.* 23: 71-77.
4. Holsboer F (1999) The rationale for cotricotropin-releasing hormone receptor (CRH-R) antagonists to treate depression and anxiety. *J. Psychiatr. Res.* 33: 181-214.
5. Holsboer F (1999) The rationale for cotricotropin-releasing hormone receptor (CRH-R) antagonists to treate depression and anxiety. *J. Psychiatr. Res.* 33: 181-214.




## Limited Use Label License Agreement

In addition to the General Terms & Conditions of Sale for Products and Services section, this Product is subject to Limited Use Label License Agreement. Please go to https://www.eurofinsdiscoveryservices.com/cms/cms-content/misc/legal-disclaimer/ for more information.